Results 91 to 100 of about 284 (126)

Aprocitentans effektivitet, säkerhet och tolerabiltetet som behandling av hypertoni

openaire   +1 more source

Effects of Multiple‐Dose Administration of Aprocitentan on the Pharmacokinetics of Rosuvastatin

Clinical Pharmacology in Drug Development, 2020
AbstractAprocitentan is an investigational, orally active, dual, endothelin receptor antagonist that targets a novel pathway in the treatment of difficult‐to‐control (resistant) hypertension. The drug‐drug interaction potential of aprocitentan on the breast cancer resistance protein (BCRP) transporter substrate rosuvastatin was investigated in this ...
Patricia N Sidharta, Jasper Dingemanse
exaly   +4 more sources

Aprocitentan (a Dual Endothelin-Receptor Antagonist) for Treatment-Resistant Hypertension

Journal of Cardiovascular Pharmacology, 2021
Abstract: Treatment-resistant hypertension (TRH) is associated with increased cardiovascular risks and progression of chronic kidney disease. The pathophysiology of TRH is multifactorial, including overactivity of the renin–angiotensin–aldosterone system and sympathetic nervous system, endothelial dysfunction, and volume overload.
Emily K, McCoy, Katelin M, Lisenby
openaire   +3 more sources

Dual endothelin antagonist aprocitentan for resistant hypertension (PRECISION): a multicentre, blinded, randomised, parallel-group, phase 3 trial

Lancet, The, 2022
BACKGROUND: Resistant hypertension is associated with increased cardiovascular risk. The endothelin pathway has been implicated in the pathogenesis of hypertension, but it is currently not targeted therapeutically, thereby leaving this relevant ...
John Flack, Ivor Katz, Andrew Ajani
exaly   +4 more sources

Some of the next articles are maybe not open access.

Related searches:

Pressing Update: Aprocitentan for the Treatment of Hypertension

Annals of Pharmacotherapy
Objective: This article reviews the published data including the pharmacology, efficacy, and safety of aprocitentan, a novel endothelin receptor antagonist developed to treat hypertension in conjunction with additional agents. Data sources:
Bradley Phillips, Angelina Vascimini, Chardae Whitner   +2 more
exaly   +3 more sources

Aprocitentan: First Approval

Drugs
Aprocitentan (TRYVIO™) is a once-daily oral dual endothelin A (ETA) and B (ETB) receptor antagonist developed by Idorsia Pharmaceuticals for the treatment of hypertension. The endothelin pathway has been implicated in hypertension. Aprocitentan inhibits the binding of endothelin-1 to ETA and ETB receptors, thereby preventing its deleterious effects and
Sohita Dhillon, Dhillon Sohita
exaly   +3 more sources

Aprocitentan: a new horizon in the treatment of hypertension

Expert Opinion on Pharmacotherapy
There has been a lack of novel medication classes approved for reducing blood pressure (BP) in hypertensive patients. Endothelins, powerful vasoconstricting peptides, have been at the forefront of experimental hypertension research since they were discovered in 1988.

exaly   +3 more sources

Effect of Multiple-Dose Aprocitentan Administration on the Pharmacokinetics of Midazolam in Healthy Male Subjects

European Journal of Drug Metabolism and Pharmacokinetics, 2019
Aprocitentan is an orally active dual endothelin receptor antagonist that targets a novel pathway in the treatment of difficult-to-control (resistant) hypertension. The drug-drug interaction potential of aprocitentan on cytochrome P450 (CYP) 3A enzymes was investigated in this open-label, two-treatment single-sequence study.The primary and main ...
Patricia N Sidharta, Jasper Dingemanse, Dingemanse Jasper   +2 more
exaly   +3 more sources